Coronavirus Immunity: Vaccine Data Hopeful But Unclear — Dare to Know

The Doctor Tried to Inoculate Me at That Time

Unfortunately, the little telltale bump that doctors call the “pustule” didn’t form in my case. That made it unclear if I was adequately immunized, and our doctor deemed it unwise to repeat the procedure.

Immune Systems and Vaccine Effectiveness

It all turned out fine, but it was an example of the close connection between our immune systems and vaccine effectiveness. Of course, this consideration will be vital as we deal with the pandemic.

Vigorous Immune Response Producing T-Cells

Our adaptive immune system consists of three kinds of cells. We have B-cells that create antibodies, helper T-cells that recognize viruses and killer T-cells that wipe them out.

T-Cells Targeted Spikes That Hook Onto Our Cells

In more good news, the T-cells the researchers discovered specifically target these spikes. The team also did antibody tests on blood samples that labs had on hand from before COVID-19 started circulating.

A Vaccine Might Be Able to Wipe It Out

That leads us to another article published last week, this time from the journal Nature. It reviews the status of the various efforts to find an effective vaccine against COVID-19.

Vaccine Kept a Group of Monkeys from Getting Pneumonia

In the animal trials, the vaccine kept a group of monkeys from getting pneumonia. However, they were still infected with the SARS-CoV-2 virus in their noses. Chinese scientists are also working on a vaccine, and they’ve had the same puzzling result.

Moderna Needs to Publish the Source Scientific Data

Reviewers are also challenging the Oxford results. Although the animals in the study did produce antibodies for coronavirus immunity, the levels were underwhelming.

Oxford Vaccine Might Be Strong Enough to Work in Practice

Infections in the field would probably be far less intense than the levels to which the researchers exposed the monkeys. That means that the Oxford vaccine might be strong enough to work in practice.

Every Reason to Move On to Phase Two Trials As Planned

One thing all the experts agree on is that there is every reason to move on to phase two trials as planned. Having excellent safety data but only limited efficacy results is precisely where researchers expect to be at the end of phase one.

Ensures That Decision Makers Set Policy Based on Science

The later phases of the trial should clear up most of the unanswered questions we still have at this point. They’ll accomplish that in a systematic way that scientists and doctors can relate to and apply in their work.

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
David Morton Rintoul

David Morton Rintoul

I write for those who find meaning in discoveries about space, living things, and humanity. I also write content marketing stories for select B2B clients.